Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.
V. M. Macaulay
Consultant or Advisory Role - OSI Pharmaceuticals; Roche
M. R. Middleton
No relevant relationships to disclose
S. G. Eckhardt
Consultant or Advisory Role - OSI Pharmaceuticals
Research Funding - OSI Pharmaceuticals
R. A. Juergens
Research Funding - OSI Pharmaceuticals
C. M. Rudin
Consultant or Advisory Role - Genentech; Novartis; Syndax
A. Manukyants
Employment or Leadership Position - OSI Pharmaceuticals
S. Gogov
Employment or Leadership Position - OSI Pharmaceuticals
Stock Ownership - OSI Pharmaceuticals
S. Poondru
Employment or Leadership Position - OSI Pharmaceuticals
Stock Ownership - OSI Pharmaceuticals
R. Gedrich
Employment or Leadership Position - Astellas Pharma
Stock Ownership - Astellas Pharma
S. M. Gadgeel
Consultant or Advisory Role - OSI Pharmaceuticals
Honoraria - OSI Pharmaceuticals